Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 8.33%
As of Friday, November 13, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 8.33%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. TNXP
$3.01
-0.23
-7.10%
November 13, 2026 4:00:00 PM
EST
Volume: 1,929,555
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
Commentary & Analysis
Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 7.82%
As of Thursday, November 12, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 7.82%, which has investors questioning if this is right time to buy.Michael Rose
Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 7.24%
As of Tuesday, November 10, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 7.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 8.65%
As of Monday, November 09, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 8.65%, which has investors questioning if this is right time to buy.Tudor Pop
Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 9.39%
As of Thursday, November 05, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 9.39%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | TNXP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $63.0 | $218.8 | 19% |
|
| Shares Out (Mil) | 18.4 | 55.0 | 29% |
|
| Institutional Ownership | 99.5% | 92.8% | 89% |
|
| Float (Mil) | 18.2 | 42.0 | 27% |
|
| Beta | 1.90 | 0.96 | 90% |
|
| Avg Daily Volume (000s) | 1,209 | 546 | 71% |
|
| Price Change (52-week) |
(81.5%) | 44.0% | 8% |
|
| Growth | TNXP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (19.7%) | (10.3%) | 20% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 3 | |
| Current EPS | ($2.645) | ($10.915) | ($7.003) | |
| Month Ago EPS | ($2.345) | ($9.950) | ($7.875) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($2.345) | ($9.950) | ($7.875) | |
| Year/Year Chg | (8.5%) | (25.1%) | (69.9%) | |
| Financials | TNXP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $43 | $41 | 18% |
|
| Net Income (TTM) (Mil) | ($181) | ($43) | 7% |
|
| EPS (TTM) | ($11.932) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($165) | ($35) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($28) | $-0 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | ($74) | $157 | 1% |
|
| Valuation | TNXP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.31 | 2.08 | 6% |
|
| P/E | na | 17.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TNXP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 89.3% | 68.1% | 93% |
|
| Net Margin | (420.4%) | (50.8%) | 2% |
|
| ROA | (73.1%) | (47.4%) | 8% |
|
| ROE | (84.1%) | (52.5%) | 10% |
|
| Liabilities to Assets | 17.7% | 29.7% | 11% |
|
| F-Score | 3 | 3 | 18% |
|
Tonix Pharmaceuticals Holding Corp. did not pass any screens on 11/12/2026.
